ArticleBiomaterials2016
Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer.
Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Supramolecular engineering of fibrinogen into a fibrin matrix with enhanced bioactive properties.Bioactive materials · 2027Article
- Injectable thermoresponsive hydrogel scaffold for enhanced delivery of next-generation induced neural stem cells for treatment of glioblastoma.Drug delivery and translational research · 2026Article
- Injectable thermo-responsive hydrogel scaffold for enhanced delivery of second-generation induced neural stem cells for treatment of glioblastoma.Research square · 2026Article
- Injectable Tumoricidal Neural Stem Cell-Laden Hydrogel for Treatment of Glioblastoma Multiforme-An In Vivo Safety, Persistence, and Efficacy Study.Pharmaceutics · 2024Article
- Therapeutic potential and impact of nanoengineered patient-derived mesenchymal stem cells in a murine resection and recurrence model of human glioblastoma.Bioengineering & translational medicine · 2024Article
- Review
- Revolutionizing lymph node metastasis imaging: the role of drug delivery systems and future perspectives.Journal of nanobiotechnology · 2024Review
- Article
- Injectable pH Thermo-Responsive Hydrogel Scaffold for Tumoricidal Neural Stem Cell Therapy for Glioblastoma Multiforme.Pharmaceutics · 2022Article
- Use of FLOSEAL® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy.Bioengineering & translational medicine · 2022Article
- Glioblastoma Multiforme-A Look at the Past and a Glance at the Future.Pharmaceutics · 2021Review
- Biomaterials and 3D Bioprinting Strategies to Model Glioblastoma and the Blood-Brain Barrier.Advanced materials (Deerfield Beach, Fla.) · 2021Review
- Polymeric Biomaterial Scaffolds for Tumoricidal Stem Cell Glioblastoma Therapy.ACS biomaterials science & engineering · 2020Review
- Generation and Profiling of Tumor-Homing Induced Neural Stem Cells from the Skin of Cancer Patients.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Impact of composite scaffold degradation rate on neural stem cell persistence in the glioblastoma surgical resection cavity.Materials science & engineering. C, Materials for biological applications · 2020Article
- Review
- Developing Implantable Scaffolds to Enhance Neural Stem Cell Therapy for Post-Operative Glioblastoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Gold Nanowires/Fibrin Nanostructure as Microfluidics Platforms for Enhancing Stem Cell Differentiation: Bio-AFM Study.Micromachines · 2019Article
- Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds.Journal of visualized experiments : JoVE · 2018Article
- Perspective on Translating Biomaterials Into Glioma Therapy: Lessons FromFrontiers in materials · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Tumor-homing cytotoxic stem cell (SC) therapy is a promising new approach for treating the incurable brain cancer glioblastoma (GBM). However, problems of retaining cytotoxic SCs within the post-surgical GBM resection cavity are likely to significantly limit the clinical utility of this strategy. Here, we describe a new fibrin-based transplant approach capable of increasing cytotoxic SC retention and persistence within the resection cavity, yet remaining permissive to tumoritropic migration. This fibrin-based transplant can effectively treat both solid and post-surgical human GBM in mice. Using our murine model of image-guided model of GBM resection, we discovered that suspending human mesenchymal stem cells (hMSCS) in a fibrin matrix increased initial retention in the surgical resection cavity 2-fold and prolonged persistence in the cavity 3-fold compared to conventional delivery strategies. Time-lapse motion analysis revealed that cytotoxic hMSCs in the fibrin matrix remain tumoritropic, rapidly migrating from the fibrin matrix to co-localize with cultured human GBM cells. We encapsulated hMSCs releasing the cytotoxic agent TRAIL (hMSC-sTR) in fibrin, and found hMSC-sTR/fibrin therapy reduced the viability of multiple 3-D human GBM spheroids and regressed established human GBM xenografts 3-fold in 11 days. Mimicking clinical therapy of surgically resected GBM, intra-cavity seeding of therapeutic hMSC-sTR encapsulated in fibrin reduced post-surgical GBM volumes 6-fold, increased time to recurrence 4-fold, and prolonged median survival from 15 to 36 days compared to control-treated animals. Fibrin-based SC therapy could represent a clinically compatible, viable treatment to suppress recurrence of post-surgical GBM and other lethal cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.